Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Ozone therapy and the role of the glutathione pathway.

Created on 24 Sep 2025

Authors

Salvatore Chirumbolo, Marianno Franzini, Umberto Tirelli, Luigi Valdenassi

Published in

Inflammopharmacology. Sep 24, 2025. Epub Sep 24, 2025.

Abstract

Oxygen-ozone therapy (OOT) represents a multi-target intervention that engages redox modulation, endothelial repair, nitric oxide bioavailability, and immune reprogramming. In contrast, intravenous glutathione (IV-GSH) provides only transient antioxidant support without activating upstream adaptive pathways. Using an ODE-based mechanistic model, we evaluated the contribution of the GSH/GSSG system against other ozone-activated networks. Sensitivity analysis demonstrated that GSH/GSSG accounts for only a minor fraction of the therapeutic benefit (< 10% in adults, ~ 2% in elderly), while endothelial/NO and Nrf2-driven adaptive responses dominate. Forecasted recovery trajectories over six months showed ozone rapidly drives near-complete recovery, whereas IV-GSH plateaus at negligible improvements. These results highlight that OOT is not a simple antioxidant therapy but a systemic bioregulatory treatment, particularly effective in immune, inflammatory, nociceptive, and degenerative disorders. Glutathione plays a supportive role but cannot substitute ozone's multi-pathway efficacy.

PMID:
40991178
Bibliographic data and abstract were imported from PubMed on 24 Sep 2025.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 44
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement